In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Beyond Drug-Coated Stents

Executive Summary

'Drug-coated stents' success will usher in a new era in interventional cardiology, argues Marty Leon, MD, one of the nation's top interventional cardiologists. He sees interventionalists taking the lead in new areas and expanding their presence in others, such as interventional radiology, and interventional neurology. New nanotechnologies will be used to manufacture stents to ensure better adhesion of therapeutic agents, and these will need new access technologies and imaging systems, for example.

You may also be interested in...



For 2001, A Top Eleven List

2001 was a mixed year for health-care manufacturers, characterized by real advances in cardiac device therapies, the maturing of the biotech and generics sectors, and the continued embattlement of Big Pharma. Here's the staff of IN VIVO's list of the most important trends.

Stent and Deliver

Stents have been very effective at avoiding elastic recoil by mechanically holding arteries open after balloon angioplasty. They have also, to a certain extent, alleviated the problem of restenosis, the reocclusion of the artery in the months following angioplasty. Unfortunately, however, stents don't go far enough to prevent restenosis--anywhere from 10% to 40% of patients will develop restenosis within six months of revascularization procedures--and the devices frequently result in a new, man-made and difficult-to-treat kind of restenosis, known as in-stent restenosis. Thus, device developers are putting serious development effort into enhanced stents that can carry and deliver drugs to combat restenosis locally.

Stent Wars: The Sequel--Is J&J Back?

While it's far too early to begin talking about a phoenix-like resurgence, Johnson & Johnson shows initial signs of at least shaking up what in recent years has become a far too comfortably stratified coronary stent market. J&J's Cordis Corp. received FDA approval of its new Bx Velocity stent in mid-May, several weeks earlier than anticipated.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

IV001741

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel